Liang An-Min, Mo Qin-Guo, Yang Nan-Wu, Zhao Yin-Nong, Yuan Wei-Ping
Department of General Surgery, Affiliated Tumor Hospital, Guangxi Medical University, Nanning, Guangxi, PR China.
Ai Zheng. 2004 Feb;23(2):211-4.
BACKGROUND & OBJECTIVE: Progress has been made in the field of early detection and early treatment of primary liver cancer (PLC), but many PLC patients remain unresectable, because their tumors are advanced or coexist with liver cirrhosis. Even if the tumor can be resected, the recurrent rate is more than 60%. This study aimed to investigate the efficacy of comprehensive therapy of PLC to improve the outcome.
A retrospective analysis of 607 patients with PLC received comprehensive treatment in Affiliated Tumor Hospital, Guangxi Medical University from 1985 to 2001. Among them, 423 cases were treated with various modes of hepatectomy: 134 with irregular hepatectomy, 95 with local radical resection, 123 with regular liver lobectomy or liver segment resection, 54 with semi-hepatectomy or more, 17 with hepatectomy combined with section of other organ. The other 184 nonresectable cases were treated with various combinations of therapy, such as ligation of hepatic artery, microwave coagulation, inter tumor injection of ethanol, cryosurgery, radio-frequency (RF), and intraperitoneal chemotherapy.
69.7%(423/607) of the whole group received liver resection, the overall mortality rate within one month after operation was 1.2%(5/423), and the 3-, 5-, 10-year survival rates were 42.7%(218/511), 37.5%(123/328), and 26.5%(26/98), respectively. For the resection group,the 3-, 5-, 10-year survival rates were 57.2%(203/355), 51.3%(118/230), and 35.3%(24/68), respectively. For the nonresectable group, the 3-, 5-, 10-year survival rates were 9.6%(15/156), 5.1%(5/98), and 6.7%(2/30), respectively.
Surgery-predominant comprehensive therapy is effective modality for resectable PLC. Postoperative individualized comprehensive treatment can prevent tumor recurrence and improve postoperative effect.
原发性肝癌(PLC)的早期发现和早期治疗领域已取得进展,但许多PLC患者仍无法切除,因为其肿瘤已属晚期或合并肝硬化。即便肿瘤能够切除,复发率也超过60%。本研究旨在探讨PLC综合治疗的疗效以改善预后。
回顾性分析1985年至2001年在广西医科大学附属肿瘤医院接受综合治疗的607例PLC患者。其中,423例接受了不同方式的肝切除术:134例行不规则肝切除术,95例行局部根治性切除术,123例行规则肝叶切除术或肝段切除术,54例行半肝切除术或更大范围肝切除术,17例行肝切除术联合其他器官切除。另外184例不可切除病例接受了多种治疗组合,如肝动脉结扎、微波凝固、瘤内注射乙醇、冷冻手术、射频(RF)及腹腔内化疗。
全组69.7%(423/607)接受了肝切除,术后1个月内总死亡率为1.2%(5/423),3年、5年、10年生存率分别为42.7%(218/511)、37.5%(123/328)和26.5%(26/98)。切除组的3年、5年、10年生存率分别为57.2%(203/355)、51.3%(118/230)和35.3%(24/68)。不可切除组的3年、5年、10年生存率分别为9.6%(15/156)、5.1%(5/98)和6.7%(2/30)。
以手术为主的综合治疗是可切除PLC的有效治疗方式。术后个体化综合治疗可预防肿瘤复发并提高术后疗效。